St.Louis-Cape Girardeau CCOP

描述（由申请人提供）：圣路易斯-开普吉拉多CCOP是一个 由两个独立的两州卫生服务区的四家医院组成的联合体 服务于密苏里州东部和伊利诺斯州西部的部分地区。调查人员 圣路易斯大都会区的一个或两个附属于 在过去的18年里， 多年来，在癌症治疗研究方案和最近，在癌症 控制研究。吉拉多角的调查人员与 在过去的九年里，CCOP附属于两家医院， 市在未来五年内，我们预计将积累至少60个学分 NSABP和SWOG的癌症治疗研究方案， 每年至少75个学分（新参与者和随访）， 癌症控制和预防研究。这些癌症控制信贷将是 主要来自于我们对乳腺癌预防的参与， 试验-1，前列腺癌预防试验-1和乳腺癌预防 试验-2。我们将继续为西南地区提供高质量的数据 肿瘤学小组和国家外科辅助乳腺和肠道项目 这些都是我们的研究基地，利用开发的数据管理系统 在过去的十八年里。总之，我们将继续我们出色的 过去18年在癌症治疗研究方面的表现 并扩大我们最近参与的癌症控制和预防 审判研究者过去的经验和能力， Clinical Research Associates为持续发展提供了坚实的基础 这个社区临床肿瘤学项目

DESCRIPTION (provided by applicant): The St. Louis-Cape Girardeau CCOP is a consortium of four hospitals in two separate bi-state health service areas serving parts of eastern Missouri and western Illinois. The Investigators from the St. Louis Metropolitan area are affiliated with one or both of the two hospitals in the consortium and have worked together for the past eighteen years in cancer treatment research protocols and more recently, in cancer control research studies. The Cape Girardeau Investigators have worked with CCOP for the past nine years and are affiliated with two hospitals in that city. During the next five years we expect to accrue at least sixty credits per year for cancer treatment research protocols of the NSABP and SWOG and at least seventy five credits (new participants and follow-up) per year for cancer control and prevention studies. These cancer control credits will be derived primarily from our participation in the Breast Cancer Prevention Trial-1, Prostate Cancer Prevention Trial-1 and the Breast Cancer Prevention Trial-2. We will continue to provide high quality data to the Southwest Oncology Group and the National Surgical Adjuvant Breast and Bowel Project which are our research bases, utilizing the data management system developed during the past eighteen years. In summary, we will continue our excellent performance of the past eighteen years in cancer treatment research studies and extend our more recent participation in cancer control and prevention trials. The past experience and capabilities of the Investigators and Clinical Research Associates provides a strong base for continuing development of this Community Clinical Oncology Program.